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Abstract 
Objectives: We aimed to establish the prevalence and clinical associations of anti-HMGCR in a large 
UK cohort with juvenile myositis. 
Methods: 381 patients were investigated for anti-HMGCR using ELISA. 
Results: Anti-HMGCR autoantibodies were detected in four patients (1%). These children had no or 
minimal skin rash and significant muscle disease. Muscle biopsies were considered distinctive, with 
widespread variation in fibre size, necrotic fibres and chronic inflammatory cell infiltrates. All had 
prolonged elevation of CK and all ultimately received biologic therapies.  
Conclusion: Anti- HMGCR in UK children with myositis are associated with severe disease that is 
poorly responsive to standard treatment.  
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Introduction 
Necrotising autoimmune myopathy (NAM) is a subgroup of the idiopathic inflammatory myopathies 
that is defined by common clinical and histopathological features. Patients present with high 
creatinine kinase levels and often profound weakness. On muscle biopsy, characteristic features 
include myofibre necrosis, minimal endomysial and perivascular inflammatory infiltrate, and in some 
cases focal endomysial fibrosis.(1) Despite little or no muscle inflammation, NAM usually responds to 
immunomodulatory therapy highlighting that this is an immune-mediated phenotype. It has been 
associated with two myositis specific autoantibodies; anti-SRP and more recently anti-HMG-CoA-
reductase (HMGCR).  
Patients with anti-HMGCR associated disease make up approximately 6% of adult idiopathic 
inflammatory myopathy cohorts.(2) In addition to NAM, anti-HMGCR antibodies are associated with 
statins, an intriguing finding given that HMGCR is the pharmacologic target of statins and is 
upregulated by statin use.(2) Whilst statins are typically prescribed to adult patients, anti-HMGCR 
has been reported in patients with juvenile-onset NAM but data is extremely limited.(3) 
Furthermore, 40-70% of adults with anti-HMGCR associated NAM have no history of statin exposure 
suggesting the presence of alternative disease triggers. (2, 3)  We aimed to establish the prevalence 
and clinical associations of anti-HMGCR in a large UK Juvenile Idiopathic Inflammatory Myositis 
(JIIM) cohort. 
 
Methods 
Patients 
Serum samples and matched clinical data were obtained from 381 patients with JIIM recruited to the 
UK Juvenile Dermatomyositis Cohort and Biomarker Study described previously.(4) Ethical approval 
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has been obtained (Northeast-York Research Ethics Committee 01/3/022). Parental consent and 
consent or age-appropriate assent was obtained in accordance with the declaration of Helsinki.  
Autoantibody detection 
Immunoprecipitation of all samples was performed to determine the presence of myositis specific 
and associated autoantibodies, as previously described. (5, 6) The presence of anti-HMGCR was 
determined in all samples by ELISA using recombinant antigen, as previously described. (7) Positive 
samples were confirmed by western blotting (insufficient serum for patient 3). A further 48 juvenile 
healthy controls, 21 juvenile SLE and 27 muscular dystrophy patients were found to be negative for 
anti-HMGCR. 
Immunofluorescence 
HEp2 Indirect immunofluorescence was performed at 1:40 serum dilution for all anti-HMGCR 
positive samples according to manufacturer’s instructions (Inova).  
Muscle biopsy 
Where tissue was available for re-assessment, muscle biopsies were processed, stained and scored 
(using the International JDM score tool) by an expert paediatric neuropathologist (TSJ) blinded to 
clinical data.(8, 9) 
 
Results 
Anti-HMGCR autoantibodies were detected in four of the 381 patients (1%). None had a history of 
statin exposure. They were not found in conjunction with any other myositis specific or associated 
autoantibody. All patients with anti-HMGCR had a cytoplasmic staining pattern on 
immunofluorescence, two had additional coarse speckled nuclear staining. 
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Whilst numbers were insufficient for statistical analysis, based on Childhood Myositis Assessment 
Scores (CMAS) and Physician Global assessment of disease activity visual analogue scores (PGA), 
children with anti-HMGCR were weaker and had greater disease activity, (Table 1). Consistent with 
previous reports in juvenile-onset disease CK at presentation was elevated in just 55.4% of 
patients.(10, 11) Of those patients with an elevated CK the median value was 1039 IU/L (415-
4115.25), compared to 15500 (12000-25,250) for those with anti-HMGCR.  
Patient 1 
A 4 year old girl developed a relatively slow onset muscular weakness with a lowest ever CMAS of 28 
(0-53), corresponding to a moderate degree of weakness.(12) CK at presentation was 12000. She had 
no rash. Muscle biopsy was reported to be consistent with dermatomyositis. Her highest ever PGA 
was 4.8 out of 10. She responded to initial treatment with oral methotrexate and steroids but CK 
remained elevated. Her disease flared (lowest CMAS of 33 with no rash and peak CK of 7000) when 
methotrexate was stopped after a lengthy period of remission, following which treatment was 
restarted with subcutaneous methotrexate alongside oral prednisolone. She subsequently 
responded to infliximab and entered remission. 
Patient 2  
A 13.8 year old girl presented with periorbital puffiness and hyperpigmentation with progressive 
weakness over 1-2 months. Her CK was found to be 44000. She received pulsed IV 
methylprednisolone with some improvement. Muscle biopsy revealed a destructive myopathy with 
inflammation and necrosis. One month later her CMAS score was 0 indicating very severe weakness. 
She required nasogastric feeding. She received further pulses of IV methylprednisolone, 
cyclophosphamide and subcutaneous methotrexate. Improvement in muscle power was extremely 
slow, leading to concern that there may be an additional underlying muscle disease. Further 
investigations, including MRI, electromyography and nerve conduction studies were consistent with 
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myositis. This patient was subsequently treated with azathioprine, rituximab and further 
cyclophosphamide before entering remission with infliximab.  
Patient 3  
An 11.8 year old boy presented with a six month history of evolving proximal muscle weakness. CK 
was 19000. Lack of any skin rash prompted consideration of muscular dystrophy in the differential 
diagnosis but electromyography and muscle biopsy were most consistent with an inflammatory 
myositis.  Whilst clinically this patient’s myositis was not severe, (CMAS 30-36 consistent with mild-
moderate weakness and highest ever PGA 3) his CK has been persistently elevated.  The patient had 
a poor response to methotrexate and ultimately responded clinically to rituximab. CK remains 
>1000.  
Patient 4  
A 9.4 year old girl presented with a four month history of progressive muscle weakness. An 
inflammatory rash was confined to her antecubital fossae. CMAS was 2, consistent with severe 
weakness. At presentation ALT was 600 U/L, LDH 4000 U/L and CK 12000. A liver biopsy was normal. 
MRI showed widespread muscle oedema. Following treatment with IV methylprednisolone, 
prednisolone and subcutaneous methotrexate, CMAS remained between 5 and 30 (moderate- 
severe weakness) and muscle enzymes were persistently elevated with CK >3000. Subsequent 
treatment included infliximab, IV immunoglobulin, mycophenolate mofetil and IV 
cyclophosphamide. Her highest PGA was 9.5. The poor treatment response ultimately prompted 
diagnostic reassessment with muscle biopsy, skin biopsy and weaning of all immunosuppression. The 
patient deteriorated without immunosuppression and prednisolone was reintroduced. Muscle 
biopsy showed necrosis and inflammation and whilst not typical was felt to be consistent with 
myositis. Skin biopsy revealed inflammation in the dermis favouring dermatomyositis.  Following 
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confirmation of anti-HMGCR status the patient has been re-treated with IV immunoglobulin and 
mycophenolate mofetil with a slow but clear improvement.  
Muscle biopsy 
Muscle biopsy material was available for reassessment in three patients and the written report of 
the fourth biopsy was also available. Biopsy score components are shown in Table 2. The biopsies 
were felt have similar and distinctive feature with widespread variation in fibre size, regenerating 
fibres, necrotic fibres and degenerating fibres. There were frequent fibres expressing immature 
isoforms of myosin and deposition of the membrane attack complex (MAC, C5b-C9) on the 
sarcolemma of many fibres. There were patchy dense infiltrates of chronic inflammatory cells within 
the fascicles, (Figure 1). 
 
Discussion 
Consistent with previous reports patients with anti-HMGCR presented with either profound or 
insidious onset muscle weakness.(3) Unlike affected adults however, half of our patients had 
cutaneous disease.(2, 3) Lack of skin involvement is unusual in JIIM and minimal/absent rash 
contributed to the need to actively exclude alternative diagnoses in those with anti-HMGCR. 
Remarkably, all children with anti-HMGCR underwent muscle biopsy and two electromyography; 
these invasive procedures  are not routinely used diagnostically in the UK for suspected JIIM, the 
majority of patients being diagnosed on the basis of clinical features plus laboratory and MRI results.  
Muscle biopsies were distinctive and features included those previously reported by Allenbach et al. 
with muscle fibre necrosis and degeneration/regeneration.(3) Contrary to previous reports of a 
pauci-immune necrotising myopathy, however, there was evidence of inflammation in all four 
biopsies. JIIM muscle biopsies can display a wide range of changes that may not necessarily be 
considered ‘typical’ of dermatomyositis. All patients with anti-HMGCR had an abnormal muscle 
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biopsy with a pattern of histological features that whilst not classical for dermatomyositis was 
consistent and distinctive. Recognition of this phenotype is important to ensure muscle biopsy can 
provide the maximum level of diagnostic accuracy. Earlier recognition of anti-HMGCR autoantibodies 
may aid diagnosis, prevent potentially unnecessary investigations and facilitate rapid treatment 
escalation in the absence of a good response to standard therapy. Mammen et al. recently 
confirmed the absence of anti-HMGCR in patients with genetic muscle diseases that often form the 
differential diagnosis.(13) 
Whilst rare anti-HMGCR identify an important group of JIIM patients with severe disease 
necessitating aggressive treatment. In the UK strict guidelines exist for funding biologic treatments 
and it is remarkable that all four cases ultimately received this; in comparison to just 20.7% of the 
total cohort. We noted similarities in disease presentation to those patients with anti-SRP 
autoantibodies; in whom muscle weakness is also greater and cutaneous disease less common. Less 
than one third of patients with anti-SRP however required treatment with a biologic drug and/or IV 
cyclophosphamide. It is interesting to note that while statin exposed adult patients with anti-HMGCR 
are reported to respond dramatically to treatment, statin naïve patients have been noted to be 
younger, and may be refractory to immunosuppressive therapy.(2, 14) Younger, statin-naïve patients 
with anti-HMGCR may represent a separate subgroup of patients who are  less treatment 
responsive. These data suggest that in those children with anti-HMGCR and severe weakness there is 
an argument for the early use of aggressive immunosuppression.  
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 Tables and Figure Legends 
Table 1. Summary of the characteristics of the four patients with anti-HMGCR autoantibodies 
compared to the reminder of the JIIM cohort 
Patients with anti-HMGCR were weaker, had more severe disease and had dramatically higher CK 
levels both at disease presentation and for the lowest ever recorded value. 
 
 
Table 2. International JDM score tool assessment of muscle biopsies form patients with anti-HMGCR 
 
Biopsy appearances were consistent with a destructive myopathy with high scores in the muscle 
fibre domain. All biopsies had evidence of inflammation. 
 
Figure 1. Muscle Biopsy features of patients with anti-HMGCR autoantibodies 
All three biopsies showed a similar distinctive pattern of pathology characterised by widespread 
variation in fibre size, regenerating fibres, necrotic fibres and degenerating fibres with vacuoles and 
ill-defined eosinophilic granules (A-C). The abnormal fibres were present throughout all the fascicles 
with no peri-fascicular accentuation. There were patchy dense infiltrates of chronic inflammatory 
cells within the fascicles. The infiltrate showed a prominent component made up of T-lymphocytes 
(D-CD3). There were fewer inflammatory cells in the perimysium. In all three cases, many of the 
fibres expressed a developmental isoform of myosin (E-Neonatal myosin). Staining for the 
membrane attack complex (MAC)(C5b-9) of the complement cascade highlighted necrotic fibres but 
also outlined the sarcolemma of many of the non-necrotic fibres (F). Capillary deposition of MAC 
was not seen. Scale bars-100µm 
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Tables  
 
Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but 
clinically important subset of patients. 
Table 1. Summary of the characteristics of the four patients with anti-HMGCR autoantibodies 
compared to the reminder of the JIIM cohort 
Patients with anti-HMGCR were weaker, had more severe disease and had dramatically higher CK 
levels throughout their disease course. 
P
at
ie
n
t 
Skin 
rash 
Gender 
Age at 
disease 
onset 
(years) 
Lowest 
CMAS 
(0-53) 
Highest 
PGA 
(0-10) 
CK at 
onset 
(IU/L) 
CK at 6 
months 
post-
diagnos
is (IU/L) 
CK at 
12 
months 
post-
diagnos
is (IU/L) 
Lowest 
CK 
(IU/L) 
1 No Female 4 28 4.8 12,180 1,275 278 231 
2 Minimal Female 13 0 8.3 44,002 404 13,065 251 
3 No Male 11 36 3 19,000 4,702 4,038 1,527 
4 Minimal Female 9 2 9.5 12,662 2,004 4,638 2,241 
Median (IQR) for patients 
with anti-HMGCR 
10.6 
(7.5-
12.3) 
15 (1.8-
30) 
6.6 
(4.4-
8.6) 
15,500 
(12,000
-
25,250) 
1,057 
(1,057-
2,679) 
4,338 
(3,098-
6,744) 
889 
(246-
1705.5) 
Median (IQR) for all 381 
patients  
6.8 
(3.9-
10.1) 
40 (24-
47.3) 
4 (2.2-
7) 
225 
(78-
1,191.5
)a 
65 (41-
106)b 
88 (60-
114)c 
56 (37-
82.5) 
 
a. Median for those with a raised CK 1,039 (415-4,115.25) 
b. CK available between 4 and 8 months for 60 patients 
c. CK available between 10 and 14 months for 48 patients 
CMAS: Childhood myositis Assessment Score (0-53) 
PGA: Physician Global Assessment visual analogue score of disease activity (0-10) 
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Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies 
identify a rare but clinically important subset of patients. 
Table 2. Muscle biopsy score breakdown for patients with anti-HMGCR 
Biopsy appearances were consistent with a destructive myopathy with high scores in 
the muscle fibre domain. All biopsies had evidence of inflammation. Muscle biopsies 
were analysed using the JDM muscle biopsy score tool as previously described by 
Wedderburn et al. (8,9) 
  Patient 
1 
Patient 
2 
Patient 
3 
Patient 
4 
Any treatment pre-biopsy? No Yes No Yes 
In
fl
am
m
at
o
ry
 d
o
m
ai
n
 
CD3+ endomysial infiltration 
(0-2) 
2 
N
o
 t
is
su
e 
av
ai
la
b
le
 f
o
r 
h
is
to
lo
gi
ca
l r
e-
as
se
ss
m
en
t.
 a
 
2 1 
CD3+ perimysial infiltration (0-
2) 
0 1 0 
CD3+ perivascular infiltration 
(0-2) 
2 2 0 
CD68+ endomysial infiltration 
(0-2) 
2 2 1 
CD68+ perimysial infiltration 
(0-2) 
1 2 1 
CD68+ perivascular infiltration 
(0-2) 
2 2 1 
Domain total 9 11 4 
V
as
cu
la
r 
d
o
m
ai
n
 Capillary dropout (0-1) 0 0 0 
Arterial abnormality (0-1) 0 0 0 
Infarction (0-1) 0 0 0 
Domain total 0 0 0 
M u
s
cl e fi b
r
e d o m ai n
 MHC I over-expression (0-1) 1 1 0 
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Perifascicular atrophy 2 2 1 
Neonatal myosin (0-1) 1 1 1 
Fibre atrophy (0-1) 1 1 0 
Regeneration/degeneration/ne
crosis perifascicular 
2 2 2 
Regeneration/degeneration/ne
crosis non-perifascicular 
2 2 2 
Internal myonuclei in non-
basophilic otherwise normal 
fibres (0-1) 
1 1 1 
Domain total 10 10 7 
C
o
n
n
ec
ti
v
e 
ti
ss
u
e 
d
o
m
ai
n
 
Any endomysial fibrosis (0-1) 1 1 1 
Any perimysial fibrosis (0-1) 0 1 0 
Domain total 1 2 1 
Total score (0-27) 20 23 12 
VAS severity (0-10) 7 9 7 
MAC (C5-9b) staining of necrotic fibres Yes Yes Yes 
 
a. Original muscle biopsy report comments on muscle fibre necrosis and inflammation. Biopsy 
findings were felt to be supportive of a diagnosis of a myositis in the correct clinical context 
but not diagnostic on their own. 
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Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but 
clinically important subset of patients. 
Figure 1. Muscle Biopsy features of patients with anti-HMGCR autoantibodies 
All three biopsies showed a similar distinctive pattern of pathology characterised by widespread 
variation in fibre size, regenerating fibres, necrotic fibres and degenerating fibres with vacuoles and 
ill-defined eosinophilic granules (A-C). The abnormal fibres were present throughout all the fascicles 
with no peri-fascicular accentuation. There were patchy dense infiltrates of chronic inflammatory 
cells within the fascicles. The infiltrate showed a prominent component made up of T-lymphocytes 
(D-CD3). There were fewer inflammatory cells in the perimysium. In all three cases, many of the 
fibres expressed a developmental isoform of myosin (E-Neonatal myosin). Staining for the 
membrane attack complex (MAC)(C5b-9) of the complement cascade highlighted necrotic fibres but 
also outlined the sarcolemma of many of the non-necrotic fibres (F). Capillary deposition of MAC 
was not seen. Scale bars-100µm 
 
 
 
